RALLYBIO CORP (RLYB:NASDAQ)
$15.89 0.16 (1.0172%)
Analysed RALLYBIO CORP (RLYB:NASDAQ) News Sources
Does Short Squeeze Attention and AI Advances Alter the Bull Case for Recursion Pharmaceuticals (RXRX)?
27-09-2025
yahoo.com
Stock Splits Matter: Notable Splits in 2025 and What’s Happening in 2026
04-02-2026
247wallst.com
Stock Splits Matter: What’s Coming Up This Month?
04-02-2026
247wallst.com
Candid, in a reverse merger with RallyBio, to go public
02-03-2026
biopharmadive.com
Rallybio to acquire Candid Therapeutics
03-03-2026
pharmaceutical-technology.com
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
01-06-2026
yahoo.com
RallyBio tries again for reverse merger, this time with Avenzo
01-06-2026
biopharmadive.com
RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own?
01-06-2026
stocktwits.com
Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing
22-06-2026
yahoo.com
VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development
24-06-2026
yahoo.com
What is the current price of RALLYBIO CORP (RLYB:NASDAQ)?
The current price of RALLYBIO CORP (RLYB:NASDAQ) is $15.89.
RALLYBIO CORP (RLYB:NASDAQ) absolute price change since previous trading day?
The absolute price change of RALLYBIO CORP (RLYB:NASDAQ) since the previous trading day is $0.16.
RALLYBIO CORP (RLYB:NASDAQ) percentage price change since previous trading day?
The percentage price change of RALLYBIO CORP (RLYB:NASDAQ) since the previous trading day is 1.0172%.
What is the most recent average sentiment score for RALLYBIO CORP (RLYB:NASDAQ)?
The most recent average sentiment score for RALLYBIO CORP (RLYB:NASDAQ) is 78 out of 100.
What is the most recent average sentiment for RALLYBIO CORP (RLYB:NASDAQ)?
The most recent sentiment for RALLYBIO CORP (RLYB:NASDAQ) is .
SEC-8K** Filing Available For RALLYBIO CORP (RLYB:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.